Literature DB >> 19285081

Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses.

Coral-Ann M Almeida1, Steven G Roberts, Rebecca Laird, Elizabeth McKinnon, Imran Ahmed, Katja Pfafferott, Joanne Turley, Niamh M Keane, Andrew Lucas, Ben Rushton, Abha Chopra, Simon Mallal, Mina John.   

Abstract

The enzyme linked immunospot (ELISpot) assay is a fundamental tool in cellular immunology, providing both quantitative and qualitative information on cellular cytokine responses to defined antigens. It enables the comprehensive screening of patient derived peripheral blood mononuclear cells to reveal the antigenic restriction of T-cell responses and is an emerging technique in clinical laboratory investigation of certain infectious diseases. As with all cellular-based assays, the final results of the assay are dependent on a number of technical variables that may impact precision if not highly standardised between operators. When studies that are large scale or using multiple antigens are set up manually, these assays may be labour intensive, have many manual handling steps, are subject to data and sample integrity failure and may show large inter-operator variability. Here we describe the successful automated performance of the interferon (IFN)-gamma ELISpot assay from cell counting through to electronic capture of cytokine quantitation and present the results of a comparison between automated and manual performance of the ELISpot assay. The mean number of spot forming units enumerated by both methods for limiting dilutions of CMV, EBV and influenza (CEF)-derived peptides in six healthy individuals were highly correlated (r>0.83, p<0.05). The precision results from the automated system compared favourably with the manual ELISpot and further ensured electronic tracking, increased through-put and reduced turnaround time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285081      PMCID: PMC3818523          DOI: 10.1016/j.jim.2009.02.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells.

Authors:  Annika C Karlsson; Jeffrey N Martin; Sophie R Younger; Barry M Bredt; Lorrie Epling; Rollie Ronquillo; Arjun Varma; Steven G Deeks; Joseph M McCune; Douglas F Nixon; Elizabeth Sinclair
Journal:  J Immunol Methods       Date:  2003-12       Impact factor: 2.303

2.  CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays.

Authors:  Christian R Kreher; Markus T Dittrich; Robert Guerkov; Bernhard O Boehm; Magdalena Tary-Lehmann
Journal:  J Immunol Methods       Date:  2003-07       Impact factor: 2.303

3.  Measurement of cytokine release at the single cell level using the ELISPOT assay.

Authors:  Josephine H Cox; Guido Ferrari; Sylvia Janetzki
Journal:  Methods       Date:  2006-04       Impact factor: 3.608

4.  Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.

Authors:  Uma Malhotra; Fusheng Li; Jessica Nolin; Megan Allison; Hong Zhao; James I Mullins; Steve Self; M Juliana McElrath
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 5.  Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy.

Authors:  Ajit Lalvani
Journal:  Chest       Date:  2007-06       Impact factor: 9.410

6.  High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection.

Authors:  Georg M Lauer; Eleanor Barnes; Michaela Lucas; Joerg Timm; Kei Ouchi; Arthur Y Kim; Cheryl L Day; Gregory K Robbins; Deborah R Casson; Markus Reiser; Geoffrey Dusheiko; Todd M Allen; Raymond T Chung; Bruce D Walker; Paul Klenerman
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

7.  Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus.

Authors:  Mohamad Aljofan; Matteo Porotto; Anne Moscona; Bruce A Mungall
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

8.  Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.

Authors:  Holden T Maecker; Jeffrey Hassler; Janice K Payne; Amanda Summers; Karrie Comatas; Manar Ghanayem; Michael A Morse; Timothy M Clay; Herbert K Lyerly; Sonny Bhatia; Smita A Ghanekar; Vernon C Maino; Corazon Delarosa; Mary L Disis
Journal:  BMC Immunol       Date:  2008-03-17       Impact factor: 3.615

  8 in total
  12 in total

Review 1.  Therapeutic cancer vaccines: the latest advancement in targeted therapy.

Authors:  Marijo Bilusic; Ravi A Madan
Journal:  Am J Ther       Date:  2012-11       Impact factor: 2.688

2.  Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.

Authors:  Rowena A Bull; Preston Leung; Silvana Gaudieri; Pooja Deshpande; Barbara Cameron; Melanie Walker; Abha Chopra; Andrew R Lloyd; Fabio Luciani
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

3.  Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses.

Authors:  Coral-Ann M Almeida; Steven G Roberts; Rebecca Laird; Elizabeth McKinnon; Imran Ahmad; Niamh M Keane; Abha Chopra; Carl Kadie; David Heckerman; Simon Mallal; Mina John
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

4.  Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes.

Authors:  Coral-Ann M Almeida; Corine Bronke; Steven G Roberts; Elizabeth McKinnon; Niamh M Keane; Abha Chopra; Carl Kadie; Jonathan Carlson; David W Haas; Sharon A Riddler; Richard Haubrich; David Heckerman; Simon Mallal; Mina John
Journal:  J Immunol       Date:  2011-08-05       Impact factor: 5.422

5.  Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Authors:  Dilbinder K Gill; Yunda Huang; Gail L Levine; Anna Sambor; Donald K Carter; Alicia Sato; Jakub Kopycinski; Peter Hayes; Bridget Hahn; Josephine Birungi; Tony Tarragona-Fiol; Hong Wan; Mark Randles; Andrew Raxworthy Cooper; Aloysius Ssemaganda; Lorna Clark; Pontiano Kaleebu; Steven G Self; Richard Koup; Blake Wood; M Juliana McElrath; Josephine H Cox; John Hural; Jill Gilmour
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

6.  Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.

Authors:  Katja Pfafferott; Pooja Deshpande; Elizabeth McKinnon; Shahzma Merani; Andrew Lucas; David Heckerman; Simon Mallal; Mina John; Silvana Gaudieri; Michaela Lucas
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

7.  Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T Cell ELISPOT Assays.

Authors:  Stefanie Kuerten; Helena Batoulis; Mascha S Recks; Edith Karacsony; Wenji Zhang; Ramu A Subbramanian; Paul V Lehmann
Journal:  Cells       Date:  2012-07-30       Impact factor: 6.600

8.  Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies.

Authors:  Hari Ramachandran; Jessica Laux; Ioana Moldovan; Richard Caspell; Paul V Lehmann; Ramu A Subbramanian
Journal:  Cells       Date:  2012-07-25       Impact factor: 6.600

Review 9.  Macrophage heterogeneity in respiratory diseases.

Authors:  Carian E Boorsma; Christina Draijer; Barbro N Melgert
Journal:  Mediators Inflamm       Date:  2013-02-27       Impact factor: 4.711

10.  Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

Authors:  Joseph W Kim; Marijo Bilusic; Christopher J Heery; Ravi A Madan
Journal:  Cancers (Basel)       Date:  2012-11-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.